



## (51) International Patent Classification:

*C07D 487/04* (2006.01) *A61P 5/38* (2006.01)  
*A61K 31/407* (2006.01)

## (21) International Application Number:

PCT/US2013/021521

## (22) International Filing Date:

15 January 2013 (15.01.2013)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/587,280 17 January 2012 (17.01.2012) US

(71) Applicant (for all designated States except US): **NO-VARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

## (72) Inventors; and

(71) Applicants (for US only): **SUTTON, Paul** [US/US]; c/o Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936-1080 (US). **LOESER, Eric** [US/US]; c/o Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936-1080 (US).

(74) Agent: **HOUGHTON, Gregory**; Novartis Pharmaceuticals Corporation, Patent Department, Bldg. 101, One Health Plaza, East Hanover, New Jersey 07936-1080 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


## Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

## Published:

— with international search report (Art. 21(3))

(54) Title: NEW FORMS AND SALTS OF A DIHYDROPYRROLO[1,2-C]IMIDAZOLYL ALDOSTERONE SYNTHASE OR AROMATASE INHIBITOR



(I)

(57) Abstract: The invention relates to a phosphate salt or a nitrate salt of 4-(R)-6,7- dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl-3-fluoro-benzonitrile having following formula: especially in crystalline form, and specific forms of these salts, as well as related invention embodiments. The salts and salt forms allow for the prophylactic and/or therapeutic treatment of aldosterone synthase and/or aromatase mediated diseases or disorders such as Cushing's disease.